Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OmerosSTU:3O8 +3.13%33 EBITDA Margin % is 50.63% as of Jun. 2026. GuruFocus rates STU:3O8 with a GF Score™ of 33/100. The stock has 6 warning signs investors should review. Among 942 Biotechnology companies, Omeros ranks better than 91.83% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Omeros's EBITDA for the
three
months ended in Jun. 2026 was €12.54 Mil. Omeros's Revenue for the
three
months ended in Jun. 2026 was €24.76 Mil. Therefore, Omeros's EBITDA margin for the quarter that ended in Jun. 2026 was 50.63%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Omeros EBITDA Margin % Related Terms
Omeros EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Omeros's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:3O8 vs STTK, BBOT, XOMA: EBITDA Margin % Comparison
For the Biotechnology subindustry, Omeros's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omeros EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Omeros's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Omeros's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omeros (STU:3O8) has a EBITDA Margin % of 50.63% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Omeros and its competitors. According to the industry distribution chart, Omeros ranks #77 out of 942 companies in the Biotechnology industry, placing it in the top 8.2%.
Is Omeros' EBITDA Margin % too high?
Omeros' current EBITDA Margin % is 50.63%. Based on the distribution chart, Omeros ranks #77 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Omeros has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Omeros' EBITDA Margin % compare to STTK and BBOT?
According to the Biotechnology industry distribution chart, Omeros ranks #77 out of 942 companies for EBITDA Margin %. This places Omeros in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Omeros and its competitors. Omeros's current EBITDA Margin % is 50.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omeros stock overvalued right now?
Omeros (STU:3O8) has a current EBITDA Margin % of 50.63%. The current EBITDA Margin % is 50.63%. Omeros' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Omeros (STU:3O8), the current EBITDA Margin % is 50.63% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
33GF Score
Get the complete analysis for STU:3O8
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:3O8 has been successfully added to your 
